FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL								
	OMB Number: 3235-028 Estimated average burden								
	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Alleva Lawrence M</u>				2. Issuer Name and Ticker or Trading Symbol Mersana Therapeutics, Inc. [ MRSN ]					(Ch	5. Relationship of Reporting Person(s) (Check all applicable)  X Director 1			Ssuer Owner		
(Last)	`	irst) IERAPEUTICS,	(Middle) INC.		3. Date of Earliest Transaction (Month/Day/Year) 06/11/2021						Officer below)	(give title	Other below	(specify )	
840 MEMORIAL DRIVE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	A	02139									X Form fi	led by More	Reporting Per than One Re	
(City)	(S	tate)	(Zip)												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			Transactior ate lonth/Day/Y	Execution Date,		3. Transaction Code (Instr. 5) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s Formally (D) (ollowing (I) (I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		Code	nsaction of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$14.9	06/11/2021		A		25,050		(1)	06/10/2031	Common Stock	25,050	\$0	25,050	D	

## **Explanation of Responses:**

1. The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc.

/s/ Brian DeSchuytner , as Attorney-in-Fact

06/15/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.